TAM DUC CARDIOLOGY HOSPITAL JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 673-26/CV-TD

CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC

Digitally signed by CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC
DN: C=VN, S=HỒ CHÍ MINH, L=Quận 7, CN=CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC, OID.0.9.2342.19200300.100.1.1=MST:0302668322
Reason: I am the author of this document
Location:
Date: 2026-08-19 09:59:24

Ho Chi Minh City, August 19, 2026

To: - State Securities Commission;
- Hanoi Stock Exchange.

Company name	:	**Tam Duc Cardiology Hospital Joint Stock Company**	
Stock code	:	TTD	
Head office	:	No. 04 Nguyen Luong Bang, Tan My Ward, Ho Chi Minh City	
Telephone	:	1900 561539	Fax: (028) 5411 0029
Information disclosure officer	:	Nguyen Ngoc Chieu	Position: Chairman of the Board of Directors
Type of information disclosure:	:	☑ 24 h ☐ Required ☐ Extraordinary ☐ Periodic	
Content of information disclosure	:		

Information disclosure regarding the Board of Directors' Resolution No. VII.16.01/NQ-HDQT dated August 18, 2026, approving the operating results for the first six months of 2026 and the first interim dividend payment for 2026 at 5% of par value, with the record date being September 7, 2026 and the dividend payment date being September 15, 2026 (the full text of Board of Directors' Resolution No. VII.16.01/NQ-HDQT is attached).

This information was disclosed on the website of Tam Duc Cardiology Hospital Joint Stock Company at https://www.tamduchearthospital.com on August 19, 2026.

We hereby affirm that the information disclosed herein is true and accurate and take full legal responsibility for the content of the disclosed information.

INFORMATION DISCLOSURE OFFICER

M.S.D.N: 0302668322 - C.T.C.P. CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC QUẬN 7 - T.P HỒ CHÍ MINH

DR. NGUYEN NGOC CHIEU
CHAIRMAN OF THE BOARD OF DIRECTORS

Recipients:
- As above;
- File: VT, VP.

04 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh City, Vietnam
Tel: 1900 561 539 - Hotline: 0903.052.432
Website: https://www.tamduchearthospital.com - Email: hospital@tamduchearthospital.com

TAM DUC CARDIOLOGY HOSPITAL JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 53-26/TB-TD

Ho Chi Minh City, August 19, 2026

NOTICE

Regarding the Record Date for Exercising the Right to the First Interim Cash Dividend Payment for 2026

To: Vietnam Securities Depository and Clearing Corporation (VSDC)

Issuer name: Tam Duc Cardiology Hospital Joint Stock Company

Trading name: Tam Duc Cardiology Hospital Joint Stock Company

Head office: No. 04 Nguyen Luong Bang, Tan My Ward, Ho Chi Minh City

Telephone: 1900 561539 Fax: (028) 5411 0029

Tam Duc Cardiology Hospital Joint Stock Company hereby notifies the Vietnam Securities Depository and Clearing Corporation (VSDC) of the record date for preparing the list of securities holders as follows:

Securities name: **Shares of Tam Duc Cardiology Hospital Joint Stock Company**

Stock code: **TTD**

Type of securities: Common Shares

Par value: 10,000 VND/share

Trading platform: UPCOM

Record date: **September 7, 2026**

1. Reason and purpose

- First Interim Cash Dividend Payment for 2026

2. Specific details

- Dividend Rate:

+ For shares: 5% per share (01 share receives 500 VND)

- Payment date: September 15, 2026

- Payment location:

+ For deposited securities: Securities holders shall complete the procedures for receiving dividends at the depository members where their securities depository accounts are opened.

+ For non-deposited securities: Securities holders shall complete the procedures for receiving dividends at Tam Duc Cardiology Hospital Joint Stock Company, No. 04 Nguyen Luong Bang, Tan My Ward, Ho Chi Minh City, on working days of the week, starting from September 15, 2026, and shall present their Citizen ID Card/ID Card.

Vietnam Securities Depository and Clearing Corporation is requested to prepare and send to our Company the list of securities holders as of the aforementioned record date via VSDC's electronic communication portal.

LEGAL REPRESENTATIVE
CHAIRMAN OF THE BOARD OF DIRECTORS

CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC

DR. NGUYEN NGOC CHIEU

Recipients:
- As above;
- Hanoi Stock Exchange;
- File: VT, VP.

* ***<u>Attached Documents</u>***
Resolution of the 2026 General Meeting of Shareholders dated April 24, 2026;
Resolution of the Board of Directors VII dated August 18, 2026.

TAM DUC CARDIOLOGY HOSPITAL
JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 01.2026/NQ-ĐHCĐ

Ho Chi Minh City, April 24, 2026

RESOLUTION

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Pursuant to the Charter of Tam Duc Cardiology Hospital Joint Stock Company approved by the General Meeting of Shareholders on April 28, 2022;
- Pursuant to Resolution No. VII.11/NQ-HĐQT dated March 2, 2026, and Notice No. 08-26/CV-TĐ issued by the Chairman of the Board of Directors on March 3, 2026, and based on the list of shareholders entitled to attend and vote at the 2026 Annual General Meeting of Shareholders as of the record date of March 24, 2026, as provided by the Vietnam Securities Depository and Clearing Corporation;

  On April 24, 2026, at 08:17a.m., at Tam Duc Cardiology Hospital, No. 4 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh City, the 2026 Annual General Meeting of Shareholders was convened with 109/278 shareholders attending, representing 13,658,992 shares, equivalent to 87,83% of the Company's total outstanding shares (13,658,992 / 15,552,000 shares).
- Pursuant to the Vote Counting Record of the Vote Counting Committee of the 2026 General Meeting of Shareholders dated April 24, 2026;
- Pursuant to the Meeting Minutes of the 2026 Annual General Meeting of Shareholders of Tam Duc Cardiology Hospital Joint Stock Company dated April 24, 2026.

The meeting discussed and unanimously approved the Resolution with the following contents:

Article 1. APPROVAL OF THE 2025 PERFORMANCE REPORT AND 2025 AUDITED FINANCIAL STATEMENTS

Regarding professional activities: In 2025, medical examination activities *were equivalent to* 2024 (81,083/ 81,428). Inpatient treatment *increased by 5%* compared to 2024 (4,565/ 4,344). A total of *270 surgical cases* were performed, *a decrease of 24% compared to 2024 (270/355).* Interventional cardiology *increased by 4%* compared to 2024 (1,755/1,689). Cardiac electrophysiology activities in 2025 *increased by 10%* compared to 2024 (507/461). Paraclinical services in 2025 *increased by 3%* compared to 2024 (1,014,560/ 984,869).

Regarding financial performance:

	2025 Plan	*2025 Actual*
Total revenue:	VND 750 billion	VND 846.1 billion
Profit before tax:	VND 92 billion	VND 108.2 billion
Profit after tax:	VND 84 billion	VND 95.7 billion

The financial results for 2025 exceeded the plan, with revenue increasing by 12.8%.

Profit before tax reached VND 108.2 billion, an increase of 17.7% compared to the 2025 plan.

The pre-tax profit/total revenue ratio for 2025 is *12.79% (compared to 12.1% in 2024).*

Voting: 100% approval

Article 2. APPROVAL OF THE SUPERVISORY BOARD'S REPORT FOR 2025

Voting: 100% approval

Article 3. APPROVAL OF THE PROFIT DISTRIBUTION PLAN FOR 2025. THE DIVIDEND RATE FOR 2025 IS 33% AS APPROVED BY THE 2025 GENERAL MEETING OF SHAREHOLDERS ON APRIL 25, 2025

Criteria	Amount (VND)
1. Profit After Tax for 2025	**95,735,394,301**
2. Allocation to Funds (Resolution 01.2025/NQ-ĐHCĐ dated April 25, 2025)	**6,946,474,195**
2.1. Board of Directors' Operating Fund (3.6% of PAT)	3,446,474,195
2.2. Reward and Welfare Fund	3,500,000,000
3. Remaining Profit for Dividend Distribution (3=1-2)	**88,788,920,106**
4. Dividend Distribution - Projected 33% of par value	**54,022,736,000**
4.1. First interim dividend, August 2025: 10%	16,370,526,000
4.2. Second interim dividend, February 2026: 10%	16,370,526,000
4.3. Third dividend payment (after approval by the General Meeting): 13%	21,281,684,000
5. Remaining Profit for 2025 (5=3-4)	**34,766,184,106**

Voting: 100% approval

Article 4. APPROVAL OF THE PROPOSAL TO AUTHORIZE THE BOARD OF DIRECTORS TO SELECT AN AUDIT FIRM FOR THE 2026 FINANCIAL STATEMENTS

The General Meeting of Shareholders authorizes the Board of Directors to decide on the selection of an audit firm for the 2026 financial statements.

Voting: 100% approval

Article 5. APPROVAL OF THE 2026 BUSINESS PERFORMANCE PLAN

Regarding personnel: *After 20 years of stable operation and development, the leadership and professional team of Tam Duc have matured. However, it is necessary to continue recruiting and providing advanced training in key technical positions such as emergency resuscitation, anesthesia and resuscitation, surgery, interventional cardiology, and cardiac electrophysiology, while focusing on nurturing key staff and future leadership to ensure sustainable development in the next phase.*

Regarding expertise: *In 2026, medical examination, emergency care, and inpatient treatment are expected to increase by 5% compared to 2025. The company will continue to develop specialized techniques and maintain stable professional quality, with targets including 300 cardiac surgeries, 1,500 interventional cardiac catheterizations, and 500 cardiac electrophysiology cases.*

Regarding finance:

Total revenue:	*VND 780 billion*
Profit before tax:	*VND 95 billion*
Profit after tax:	*VND 86 billion*
Dividends:	*20% of par value*

Voting: 100% approval

Article 6. APPROVAL OF THE 2026 FUND ALLOCATION PLAN

Board of Directors' Operating Fund:	3.6% of profit after tax
Reward and Welfare Fund:	VND 3.5 billion

Voting: 100% approval

Article 7. APPROVAL OF THE 2026 DIVIDEND PAYMENT PLAN

First interim dividend for 2026 at a rate of 5% of par value:	September 2026
Second interim dividend for 2026 at a rate of 5% of par value:	January 2027
Third interim dividend for 2026 at a rate of 10% of par value:	After the 2027 General Meeting of Shareholders

Voting: 100% approval

Article 8. APPROVAL OF THE PLAN FOR ISSUANCE OF SHARES TO INCREASE CHARTER CAPITAL FOR 2026 AS ATTACHED TO THE PROPOSAL NO. 02/TTr-HĐQT DATED MARCH 30, 2026 OF THE BOARD OF DIRECTORS

Voting: 100% approval

Article 9. APPROVAL OF EMPLOYEE REWARDS ON THE OCCASION OF THE 20TH ANNIVERSARY OF TAM DUC CARDIOLOGY HOSPITAL (MARCH 8, 2006 –

MARCH 8, 2026) AS ATTACHED TO PROPOSAL NO. 01-2026/TTr-HĐQT DATED MARCH 30, 2026 OF THE BOARD OF DIRECTORS

Voting: 100% approval

This Resolution was presented at the General Meeting and unanimously approved by the General Meeting of Shareholders at 10:10 a.m. on April 24, 2026.

CHAIRMAN OF THE BOARD OF DIRECTORS

DR. NGUYEN NGOC CHIEU

TAM DUC CARDIOLOGY HOSPITAL
JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Ho Chi Minh City, August 18, 2026

No.: VII.16.01/NQ-HDQT

BOARD OF DIRECTORS
TERM VII.16.01

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;*
- *Pursuant to the Charter of Tam Duc Cardiology Hospital Joint Stock Company, as approved by the General Meeting of Shareholders on April 28, 2022 and amended and supplemented on July 3, 2026;*
- *Pursuant to Resolution No. 01.2026/NQ-DHCD dated April 24, 2026 of the 2026 Annual General Meeting of Shareholders of Tam Duc Cardiology Hospital Joint Stock Company;*
- *Pursuant to the Minutes of the Meeting of the Board of Directors for Term VII of Tam Duc Cardiology Hospital Joint Stock Company held on August 18, 2026.*

Participants:

1. Dr. Nguyen Ngoc Chieu	Founder, Advisor, Chairman of the Board of Directors
2. Dr. Phan Kim Phuong	Founder, Advisor, Member of the Board of Directors
3. Dr. Chu Trong Hiep	Director of Surgery, Member of the Board of Directors
4. Mr. Pham Anh Dung	Member of the Board of Directors
5. Dr. Pham Bich Xuan	Member of the Board of Directors
6. Dr. Do Van Buu Dan	General Director

Meeting Secretary:
Ms. Nguyen Ngoc Nhu Anh
Person in Charge of Corporate Governance

RESOLUTION

Article 1. Approval of the Results of Medical Operations for the First Half of 2026:

In the first half of 2026, the number of medical examinations *increased by 4.8%* compared with the same period in 2025. In the first half of 2026, outpatient visits at the Special Examination Unit totaled 11,114, representing an increase of 7.5% compared with 10,342 visits in the same period in 2025. Inpatient admissions *decreased by 5.8%* compared with the first half of 2025. *A total of 109 surgical procedures* were performed in the first half of 2026, representing *a decrease of 17% compared with the same period in 2025.* Interventional cardiology procedures *decreased slightly* compared with the same period in 2025. Cardiac electrophysiology procedures *increased by 6.9%* compared with the same period in 2025. Diagnostic and ancillary clinical services *decreased slightly* compared with the same period in 2025.

The Board of Directors VII.16 unanimously approved the results of medical operations for the first half of 2026.

Article 2. Approval of the Financial Performance for the First Seven Months of 2026:

The financial results for the first seven months of 2026 were as follows:

	Plan 2026	*Actual - First 7 Months of 2026*
Total revenue	VND 780 billion	VND 487 billion
Profit before tax	VND 95 billion	VND 50.4 billion
Profit after tax	VND 86 billion	VND 44.7 billion

Compared with the same period in 2025, total revenue increased by 2.19%, while profit before tax decreased by 17.5% and profit after tax decreased by 17.7%.

Compared with the 2026 plan, total revenue reached 62.4% of the annual target, profit before tax reached 53.1%, and profit after tax reached 51.9%.

The profit-before-tax margin for the first seven months of 2026 was 10.35%, compared with 12.83% in the corresponding period of 2025.

During the first seven months of 2026, total revenue recorded modest growth of 2.19%, while operating revenue increased by 1.2%. The remaining growth was attributable to increases in other income and financial income. Tam Duc Hospital increased its service fees effective May 15, 2026. However, costs increased at a higher rate of 5%, resulting in a significant decline in profit. The increase in costs was mainly attributable to a higher ratio of costs of drugs and medical supplies, which increased from 54.19% to 54.86% due to changes in the revenue mix. Revenue from pharmacy operations, Interventional Cardiology, and Cardiac Electrophysiology increased. However, the profitability of pharmacy operations remained low due to regulatory limits on drug markups, while medical-supply cost ratios for Interventional Cardiology and Cardiac Electrophysiology remained high. Personnel expenses increased by 7% compared with the first seven months of 2025 due to scheduled salary increases and higher on-call allowances effective from October 2025. Insurance-related expenses increased by 5% following the increase in the regional minimum wage effective January 2026. In addition, maintenance expenses increased due to higher service prices and the addition of medical equipment requiring maintenance. Electricity, cleaning, and waste collection expenses also increased as a result of price increases imposed by service providers.

Basic earnings per share decreased due to lower profit and the adjustment to the number of shares used in the EPS calculation from 15,552,000 to 31,104,000 effective July 14, 2026.

The Board of Directors VII.16 unanimously approved the financial performance for the first seven months of 2026.

Article 3. First Interim Dividend Payment for 2026

The General Meeting of Shareholders held on April 24, 2026 approved a dividend for 2026 at 20% of par value. The first interim dividend for 2026 shall be 5% of par value and is scheduled for payment in September 2026.

The Board of Directors VII.16 unanimously resolved to pay the first interim dividend for 2026 at 5% of par value, with September 7, 2026 as the record date and September 15, 2026 as the payment date.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN OF THE BOARD OF DIRECTORS

CÔNG TY CỔ PHẦN BỆNH VIỆN TIM TÂM ĐỨC

DR. NGUYEN NGOC CHIEU

Recipients:
- Board of Directors, Supervisory Board, General Director, and Chief Financial Officer;
- File: VP.